74 results on '"García-Manero G"'
Search Results
2. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
3. P136 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
4. P128 - Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
5. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
6. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
7. IS06 - SINGLE CELL DATA
8. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
9. O04 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: SINGLE-CELL-LEVEL ANALYSIS OF SF3B1-MUTANT MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS
10. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
11. 52 - Identification of the Specific Hematopoietic Stem Cell Populations Responsible for Failure to Hypomethylating Agents in Myelodysplastic Syndromes
12. 25 - CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS)
13. PCN3 Changes in Transfusion Burden (TB), Hemoglobin (Hb), Serum Ferritin (SF), and Iron Chelation Therapy (ICT) Use in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts Treated With Luspatercept From the MEDALIST Study
14. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome
15. 35 Thrombopoietic growth factors
16. Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance
17. 289 - Impact of the Type of First-Cancer Therapy in Therapy-Related Myelodysplastic Syndromes Outcomes
18. 256 - A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)
19. 79 - Effect of Lenalidomide Exposure on Response and Outcomes in Patients with Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes (MDS)
20. 60 - Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
21. 59 - Prognostic Impact of Mutations in Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with Normal Karyotype
22. 48 - Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance
23. 43 - Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
24. 39 - Updated Results from Phase 2 Study of Guadecitabine for Patients with Untreated INT-2/High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
25. 29 - Persistence of Preleukemic Clonal Hematopoiesis after Chemotherapy is Associated with Poor Prognosis in Patients with High Risk MDS and AML
26. 320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM
27. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY
28. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)
29. 99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
30. 111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY
31. 100 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH IPSS INTERMEDIATE-1 MYELODYSPLASTIC SYNDROMES WITH RBC-TRANSFUSION-DEPENDENT ANEMIA AND THROMBOCYTOPENIA: THE QUAZAR LOWER-RISK MDS TRIAL
32. 89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
33. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?
34. 68 CCAT2 LNCRNA INDUCES DE NOVO MYELODYSPLASTIC SYNDROME IN VIVO
35. 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE
36. 14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION
37. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
38. 947O - Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml)
39. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) on Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) With Acute Promyelocytic Leukemia (APL) Treated With All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
40. P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM
41. P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis
42. P-103 Occult NRAS mutations with very low allele burden have independent prognostic significance in lower-risk myelodysplastic syndromes
43. O-024 Next-generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival
44. Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
45. 288 Point mutations in myelodysplastic syndromes: Associations with clinical features and independent predictors of overall survival
46. 181 Oral azacitidine is bioavailable and reduces DNA methylation at low doses in extended schedules: Phase I study results
47. 217 A 12-month follow-up of an ongoing prospective, non-interventional, multicenter registry in iron overloaded patients with lower-risk myelodysplastic syndromes
48. 166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study
49. 152 Clinical characteristics of therapy-related myelodysplastic syndrome
50. 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.